Landmark Medicines Advances Proprietary Nasal GLP-1 Platform Towards Human Evaluation

Contributed by: GlobeNewswire

Tags

Health

More Like This

BioLife offers a new solution for oral GLP-1 delivery

BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

PR Newswire associated0

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

Over 55,000 people already on Simple Online Healthcare's waitlist for UK's first, newly approved oral GLP-1